SCHEMBL10148153

SCHEMBL10148153

CCOC(=O)CN(Cc1ccc(OC)c(OC)c1)c1nc(-c2cccc([N+](=O)[O-])c2)cs1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.49
MAPT P10636 7/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
RECQL P46063 1/20 0.45
RAB9A P51151 1/20 0.45
ACHE P22303 1/20 0.45
ALDH1A1 P00352 5/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
PDE4B Q07343 1/20 0.43
PDE4D Q08499 1/20 0.43
GSTO1 P78417 1/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10148168 0.90 KMO (0.54) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148155 0.88 KMO (0.50) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148167 0.86 KMO (0.54) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148142 0.86 KMO (0.51) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148131 0.85 KMO (0.53) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10182851 0.85 KMO (0.57) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148149 0.84 KMO (0.49) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148145 0.84 KMO (0.49) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148150 0.83 KMO (0.56) KMOMAPTMEN1KMT2ARECQL
SCHEMBL10148156 0.83 KMO (0.54) KMOMAPTMEN1KMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710237-B2 Small molecule inhibitors of kynurenine-3-monooxygenase THE J. DAVID GLADSTONE INSTITUTE (US) 2014-04-29 US disclosed
US-20120022052-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022052-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE KMO, KYNU, TDO2 KMO 1/4885MAPT 898/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.